Importance of radioiodine dosage in the treatment of patients with toxic nodular and toxic multinodular goiter
Küçük Resim Yok
Tarih
2010
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Amaç: Toksik multinodüler guatr (TMNG) ve toksik nodüler guatr (TNG) hastalarında verilen radyoaktif iyot (RAI) tedavisinin dozla ilgili etkinliğini ve yan etkilerini değerlendirmek Gereç ve Yöntem: Çalışmamıza 2003-2006 yılları arasında hastanemizdeki klinik muayene ve laboratuvar testleri sonucu TMNG ve TNG tanısı almış 57 hasta dahil edildi. Hastalara tiroid fonksiyon testleri (TFT), tam kan sayımı, biyokimya testleri, tiroid ultrasonografi (TUSG), tiroid sintigrafisi ve 4/24 saatlik RAI tedavisi gören hastalarda radyoaktif iyot uptake testleri uygulanarak tanı konuldu. RAI tedavisi gören hastalarda TUSG ve TFT radyoaktif iyot tedavisi öncesi ve tedaviden 12 ay sonra tekrar değerlendirildi. RAI tedavi öncesi ve sonrası tiroid loblarının ve nodüllerin volümleri değerlendirildi. Bulgular: TMNG ve TNG hastalarına uygulanan ortalama RAI tedavi dozu 15.6 mCi idi. Tedavinin 12. ayında hastaların %52.6’sında (30/57) ötiroidizm ve %26.4’ünde (15/57) hipotiroidizm gelişirken sadece %21’inin (12/57) tirotoksik kaldığı izlendi. Hem tiroid loblarında hem de nodüllerin volümlerinde başlangıç boyutlarına göre istatistiksel olarak belirgin azalma vardı (p0.001). RAI tedavi dozu ile tiroid loblarının ve nodüllerin volümündeki azalmada anlamlı bir fark yoktu. On iki aylık takip sırasında hipotiroidi dışında hiçbir yan etki rapor edilmedi. Sonuç: RAI tedavisi, TMNG ve TNG hastalarında başarılı bir şekilde hastaların semptomlarını kontrol etmiştir. RAI tedavisi, hem tiroid lobları üzerinde hem de nodüller üzerinde yararlı etkisini dozdan bağımsız olarak göstermektedir. Ortalama 15 mCi RAI tedavisi TMNG ve TNG hastalarının tedavisinde yeterlidir.
Aim: Our aim was to evaluate the dose-related effects and side effects of radioactive iodine (RAI) treatment on toxic multinodular goiter (TMNG) and toxic nodular goiter (TNG) patients. Material and Methods: Our study includes 57 patients diagnosed with TNG and TMNG, as a result of clinical examination and labotatory tests, in our hospital between the years 2003-2006. Patients were diagnosed through complete blood count, biochemical tests, thyroid function tests (TFT), thyroid ultrasonography (TUSG), thyroid scintigraphy and 4/24 hours radioactive iodine uptake (RAIU) test. For the patients receiving RAI treatment, TFT and TUSG were repeated at 12th month controls. The volumes of thyroid lobes and nodules were compared by TUSG before and after treatment. Results:Mean 15.6 mCi RAI treatment was given to patients with TMNG and TNG. After a 12-month treatment, euthyroidism developed in 30/57 (52.6%) and hypothyroidism in 15/57 (26.4%) of patients, but 12/57 (21%) of patients were still thyrotoxic. Decrease in thyroid lobe and nodule volumes was statistically significant (p<0.001). No significant difference was observed between RAI dosage and percentage decrease in the thyroid lobes and nodules. At the 12th month follow-up, no side effects, except hypothyroidism, were observed. Conclusions: RAI treatment is successful in controlling the disease and symptoms in TMNG and TNG. Its beneficial effect on thyroid lobe and nodule volumes as well as side effect rate is independent of RAI dosage. Mean 15 mCi RAI treatment is sufficient for disease control in TMNG and TNG.
Aim: Our aim was to evaluate the dose-related effects and side effects of radioactive iodine (RAI) treatment on toxic multinodular goiter (TMNG) and toxic nodular goiter (TNG) patients. Material and Methods: Our study includes 57 patients diagnosed with TNG and TMNG, as a result of clinical examination and labotatory tests, in our hospital between the years 2003-2006. Patients were diagnosed through complete blood count, biochemical tests, thyroid function tests (TFT), thyroid ultrasonography (TUSG), thyroid scintigraphy and 4/24 hours radioactive iodine uptake (RAIU) test. For the patients receiving RAI treatment, TFT and TUSG were repeated at 12th month controls. The volumes of thyroid lobes and nodules were compared by TUSG before and after treatment. Results:Mean 15.6 mCi RAI treatment was given to patients with TMNG and TNG. After a 12-month treatment, euthyroidism developed in 30/57 (52.6%) and hypothyroidism in 15/57 (26.4%) of patients, but 12/57 (21%) of patients were still thyrotoxic. Decrease in thyroid lobe and nodule volumes was statistically significant (p<0.001). No significant difference was observed between RAI dosage and percentage decrease in the thyroid lobes and nodules. At the 12th month follow-up, no side effects, except hypothyroidism, were observed. Conclusions: RAI treatment is successful in controlling the disease and symptoms in TMNG and TNG. Its beneficial effect on thyroid lobe and nodule volumes as well as side effect rate is independent of RAI dosage. Mean 15 mCi RAI treatment is sufficient for disease control in TMNG and TNG.
Açıklama
Anahtar Kelimeler
Endokrinoloji ve Metabolizma
Kaynak
Endokrinolojide Diyalog Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
7
Sayı
3
